Early Diagnosis of Human Prion Disease

人类朊病毒病的早期诊断

• 批准号: 8305521
• 负责人: MICHAEL D GESCHWIND
• 金额: $ 56.91万
• 依托单位: UNIVERSITY OF CALIFORNIA, SAN FRANCISCO
• 依托单位国家: 美国
• 财政年份: 2008
• 资助国家: 美国
• 起止时间: 2008-09-01 至 2013-07-31
• 项目状态: 已结题
• 来源: https://reporter.nih.gov/project-details/8305521
• 关键词: Age; Age of Onset; Alzheimer' s Disease; Autopsy; Behavioral; Biological Markers; Biopsy; Blood Transfusion; Brain; California; Cerebrospinal Fluid; Cessation of life; Classification; Clinical; Clinical Data; Cognitive; Creutzfeldt-Jakob Syndrome; Data; Degenerative Disorder; Dementia; Diagnosis; Diagnostic; Diagnostic Procedure; Diffusion; Disease; Doctor of Philosophy; Early Diagnosis; Electroencephalogram; Electroencephalography; Future; Goals; Gold; Health; Health Personnel; Hospitals; Human; Image; Laboratories; Lead; Logistic Regressions; Magnetic Resonance Imaging; Medical Records; Methods; Movement; Muscle; Nervous system structure; Neurodegenerative Disorders; Neurologist; Olfactory Epithelium; Pathology; Patients; Pattern; Phase; Primary Care Physician; Principal Investigator; Prion Diseases; Prions; Procedures; Proteins; Public Health; Recruitment Activity; Regression Analysis; Research; Risk; San Francisco; Scheme; Sensitivity and Specificity; Serological; Signs and Symptoms; Specialist; Specificity; Staging; Structure; Surrogate Markers; Symptoms; Techniques; Time; Tissues; Trees; United States; United States National Institutes of Health; Universities; Visual; base; cohort; evidence base; experience; forest; improved; meetings; mild neurocognitive impairment; neuroimaging; programs; tertiary care; transmission process; treatment program; treatment trial

DESCRIPTION (provided by applicant): Human prion diseases, such as Jakob-Creutzfeldt disease (CJD), are difficult to diagnose and are of increasing public health concern due to the risk of transmission. Our dementia program is a major referral center for prion diseases in the United States with 952 potential CJD referrals over the past six years. We also are conducting the first ever US sporadic CJD (sCJD) treatment trial, sponsored by the NIH. Unfortunately, many cases of sCJD are misdiagnosed or are diagnosed too late in the course for any future potential treatment to be effective. We, and others, have shown that brain MRI has very high sensitivity and specificity for sCJD diagnosis. Unfortunately, the most widely used diagnostic criteria for sCJD, Revised 1998 WHO Criteria, are problematic for several reasons: 1. they require symptoms that often do not occur until late in the disease course; 2. they do not use MRI; 3. they use a surrogate biomarker in the spinal fluid, the 14-3-3 protein, which we have found lacks sensitivity and specificity; and 4. they rely on certain electroencephalography (EEG) findings that have low sensitivity, particularly earlier in the disease. We will prospectively evaluate 100 patients with sCJD, 20 patients with symptomatic gCJD, and 40 patients with asymptomatic (presymptomatic gCJD) and 80 with other forms of rapidly progressive dementia (RPDs) over five years. We will conduct comprehensive assessments, including clinical, behavioral, spinal fluid surrogate marker, EEG, and MRI analyses. We will evaluate our gCJD at an age close to their predicted age of onset which will help us to identify the earliest signs of prion disease. A major focus will be to identify specific regions and patterns of abnormality on FLAIR and DTI MRI that can differentiate sCJD from other RPDs. Through this prospectively acquired data, we will devise a state of the art diagnostic scheme, using contemporary statistical classification techniques and logistic regression, for early diagnosis of sCJD. PUBLIC HEALTH RELEVANCE: Prion diseases are uniformly fatal, transmissible neurodegenerative diseases. At least one form can be transmitted by blood transfusion, and prions have now been found in several other tissues outside of the nervous system, including muscle, lymphoreticular tissues, and olfactory epithelia. Through earlier diagnosis, patients may be spared unnecessary and time-consuming diagnostic procedures and have better chance of responding to potential treatments, and the risk of transmission can be greatly reduced.

描述（由申请人提供）：人类朊病毒疾病，如雅各布-克雅氏病（CJD），很难诊断，并且由于传播的风险而引起越来越多的公共卫生关注。我们的痴呆症项目是美国朊病毒疾病的主要转诊中心，在过去六年中有952例潜在的CJD转诊。我们也正在进行美国有史以来第一次散发克雅氏病（sCJD）治疗试验，由NIH赞助。不幸的是，许多sCJD病例被误诊，或者在任何未来潜在治疗的过程中被诊断得太晚。我们和其他人已经证明，脑MRI对sCJD诊断具有非常高的敏感性和特异性。不幸的是，由于以下几个原因，最广泛使用的sCJD诊断标准，1998年修订的世卫组织标准存在问题：它们需要的症状通常直到病程晚期才出现；2. 他们不使用核磁共振成像；3. 他们在脊髓液中使用替代生物标志物，14-3-3蛋白，我们发现它缺乏敏感性和特异性；和4。它们依赖于某些敏感性较低的脑电图（EEG）结果，特别是在疾病早期。我们将在5年内对100例sCJD患者、20例有症状的gCJD患者、40例无症状（症状前）的gCJD患者和80例其他形式的快速进展性痴呆（rpd）患者进行前瞻性评估。我们将进行全面的评估，包括临床、行为、脊髓液替代标志物、脑电图和MRI分析。我们将在接近预测发病年龄的年龄评估我们的gCJD，这将有助于我们确定朊病毒疾病的最早迹象。主要的焦点将是在FLAIR和DTI MRI上识别可以区分sCJD和其他rpd的特定区域和异常模式。通过这些前瞻性获得的数据，我们将设计一个最先进的诊断方案，使用当代统计分类技术和逻辑回归，用于sCJD的早期诊断。公共卫生相关性：朊病毒疾病是致命的、可传播的神经退行性疾病。至少有一种形式可以通过输血传播，现在已经在神经系统以外的其他几种组织中发现了朊病毒，包括肌肉、淋巴网状组织和嗅上皮。通过早期诊断，患者可以避免不必要和耗时的诊断程序，并有更好的机会对潜在的治疗作出反应，并且可以大大降低传播风险。